Key Insights

Highlights

Success Rate

100% trial completion (above average)

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00001156CompletedPrimary

Assessment of Patients With Multiple Sclerosis (MS)

NCT00026728Completed

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

Showing all 2 trials

Research Network

Active Sponsors

  • National Institute of Neurological Disorders and Stroke (NINDS)1
  • National Cancer Institute (NCI)1

Related Conditions

  • Kaposis Sarcoma1
  • Vasculitis1
  • Tropical Spastic Paraparesis1
  • Htlvi Infection1
  • Multiple Sclerosis1

Activity Timeline